Form 4: Intensity CEO takes stock bonus; reverse split noted

CEO Lewis H. Bender received 37,749 fully vested shares at $6.11 as part of his 2025 bonus, lifting direct holdings to 118,549; amounts reflect a 1-for-25 reverse split effective 02/18/2026.

Summary

• On 03/26/2026, President and CEO (and Director) Lewis H. Bender acquired 37,749 shares of Intensity Therapeutics, Inc. common stock (Code A) at $6.11 per share.
• The shares were granted as a fully vested stock award under the 2021 Stock Incentive Plan in partial satisfaction of the 2025 bonus, in lieu of cash, at the CEO’s request.
• Following the transaction, Bender directly beneficially owns 118,549 shares.
• A 1-for-25 reverse split took effect on 02/18/2026; all share amounts in this report reflect that adjustment.
• The report was executed by attorney-in-fact on 03/30/2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as mixed: insider alignment and cash conservation via equity bonus are positives, but the recent 1-for-25 reverse split is a cautionary signal.

Positives

• CEO opted to take part of the 2025 bonus in equity rather than cash, aligning interests with shareholders and reducing cash outlay.
• Insider ownership increased by 37,749 shares, bringing direct holdings to 118,549 shares post-transaction.
• Immediate vesting avoids future overhang from unvested awards.

Negatives

• Issuance of 37,749 fully vested shares creates immediate dilution for existing shareholders.
• A recent 1-for-25 reverse split (effective 02/18/2026) signals prior share price pressure and may impact liquidity.
• Fully vested award provides limited incremental retention incentive.

Future Outlook

No forward-looking guidance or projections were provided; this report reflects an insider equity award and previously effected share consolidation.

Management Comments

• Award was granted as a fully vested stock award in partial satisfaction of the 2025 bonus in lieu of cash, at the CEO’s request.

Industry Context

StockSavvy.ai notes that development-stage biopharma companies commonly use equity in lieu of cash for executive compensation to preserve liquidity, and reverse splits are frequently used to meet stock exchange minimum bid price requirements and simplify capital structures.

Comparison to Industry Standards

• A 1-for-25 reverse split is at the higher end of typical biotech reverse-split ranges (often 1-for-5 to 1-for-20) used to align with Nasdaq Listing Rule 5550(a)(2) minimum $1.00 bid requirements.
• Equity in lieu of cash for executive bonuses is consistent with cash-preservation practices among pre-revenue biotech peers; immediate vesting for bonus-related stock awards is common under modern equity plans.
• Post-transaction insider ownership of 118,549 shares (post-split basis) reflects moderate alignment typical for micro-cap biotechs, where CEOs often hold on the order of tens to a few hundreds of thousands of post-split shares.

Related Party Transactions

• Fully vested stock award of 37,749 shares to CEO Lewis H. Bender under the 2021 Stock Incentive Plan as partial satisfaction of the 2025 bonus in lieu of cash at his request.

Stakeholder Impact

• Share consolidation via the 1-for-25 reverse split reduces outstanding shares and may affect trading liquidity and per-share metrics.
• Equity bonus in lieu of cash conserves company cash that would otherwise be used for compensation.
• Increased insider ownership may be perceived by shareholders as improved alignment with management.

Key Dates

Recommendation

The insider grant modestly improves alignment and conserves cash, but the presence of a recent 1-for-25 reverse split and immediate dilution from a fully vested award temper the signal. On balance, this administrative update supports a neutral stance.

Keywords

Intensity Therapeutics, INTS, Lewis H. Bender, Form 4, insider transaction, stock award, equity compensation, 2021 Stock Incentive Plan, reverse split, 1-for-25, CEO bonus, beneficial ownership